Neuronostics

The company's core technology is BioEP, a patented digital biomarker that analyzes routinely collected electroencephalogram (EEG) recordings to produce a seizure risk score. This system applies mathematical models and AI to short segments of EEG data to identify features and brain network markers that are often hidden from standard clinical observation. The technology aims to significantly reduce the time and cost associated with diagnosing epilepsy, as approximately 70% of initial EEGs are inconclusive. BioEP provides clinicians with an additional layer of objective evidence to support their diagnostic and treatment decisions, even when traditional epileptiform rhythms are absent in the EEG data.

Neuronostics operates on a software-as-a-medical-device (SaaMD) business model, providing its technology through a scalable, cloud-based platform to neurology centers, hospitals, and clinical research organizations. The company generates revenue by offering its neuro-seizure assessment software to clinicians. It has formed strategic partnerships with companies like Neuroelectrics to provide integrated EEG solutions for clinical trials, enhancing cohort identification and data analysis for pharmaceutical companies and academic partners. The company has received significant funding, including a £2.1 million seed round in April 2024 led by the Ascension Life Fund, and grants from Innovate UK and the National Institute for Health Research (NIHR). This funding supports its market expansion in the UK and Middle East, as well as efforts to secure FDA regulatory approval for the US market.